This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
No study sample size appears to have been determined in the planning phase of the study. The authors did not report any power calculations. From April 1999 to December 2000, 38 patients were randomised to any of the three groups. However, after data from this period of the study had been analysed, the enrolment of patients in the control group was stopped for ethical reasons. Additional patients (n=45) were randomised only to therapy with either ganciclovir or valacyclovir from January 2001 to January 2003. Therefore, overall, 83 patients were included in the study. Of these patients, 36 (25 males) with a mean age of 48 (+/-11) years were treated with ganciclovir. An additional 35 (26 males) with a mean age of 45 (+/-12) years received valacyclovir. Finally, the remaining 12 (6 males) patients had no prophylaxis and were managed by deferred therapy. The mean age in this group was 46 (+/-13) years.
Study design
The study used was a randomised controlled trial (RCT), which was conducted at a single centre in the Czech Republic. The patients were randomised to the three groups in a 1:1:1 ratio. When deferred therapy was discontinued, the patients were then randomised to either of the two prophylaxis interventions using a 1:1 ratio. The patients were followed up for a total of 24 months post renal transplantation (median 24; range: 12.5 -24). The authors did not report the loss to follow-up. The physicians assessing methods of CMV detection were blinded to the study group and the clinical status of the patients.
Analysis of effectiveness
The analysis of effectiveness was conducted on an intention to treat basis. The primary end point in the study was the incidence of CMV disease within the first 12 months post renal transplantation. The secondary end points included CMV DNAemia, acute rejection, patient survival, incidence of other infections, graft function and safety profile. Active CMV infection was defined as symptomatic active infection. Clinical symptoms included CMV syndrome (fever plus one or more of constitutional symptoms, leucopoenia, thrombocytopenia, or liver enzyme elevations) or tissueinvasive CMV disease. The patient groups were shown to be comparable in terms of their basic demographic characteristics, immunologic parameters and immunosuppressive therapy.
Effectiveness results
During the 12 months post renal transplantation, there were two episodes of CMV disease in 2 patients (5.7%) in the ganciclovir group and one episode of CMV disease in one patient (2.9%) in the valacyclovir group, (p=0.575). In the deferred therapy group, there were 13 CMV disease episodes in 8 patients (66.7%; p<0.001). There was no case of CMV disease after the first year post renal transplantation in either prophylactic group.
There was no case of CMV-related death or ganciclovir resistance.
The cumulative incidence of CMV DNAemia throughout the course of prophylaxis was 8.6% in the ganciclovir group and 8.8% in the valacyclovir group. At the end of 6 months after renal transplantation, although the incidences of DNAemia after stopping prophylaxis increased to 20% in the ganciclovir group and 32.4% in the valacyclovir group, (p=0.267), the differences remained highly significant in comparison with the 91.7% incidence in the deferred therapy group (p<0.001 for both ganciclovir versus deferred therapy and valacyclovir versus deferred therapy).
Compared with the deferred therapy group, there was a decrease in clinical herpes simplex viral infection in the ganciclovir group, (p=0.018), and valacyclovir group, (p=0.009).
The incidence of biopsy-confirmed acute rejection in the valacyclovir group was significantly lower than that in the ganciclovir group, (p=0.030), and deferred therapy group, (p<0.001). The biopsy-confirmed acute rejection rates at 12 months were 11.8%, 34.3% and 58.3% in the valacyclovir, ganciclovir and deferred therapy groups, respectively. The difference between the ganciclovir and deferred groups did not reach statistical significance, (p=0.087).
There were no statistically significant differences in delayed graft function incidence between the three groups, although the incidence was higher for the ganciclovir group.
Patient and graft survival rates were similar between the groups.
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The cumulative incidence of treatment failure at 24 months was significantly lower in the ganciclovir (19.8%) and valacyclovir (11.8%) groups than in the deferred therapy group (66.7%; p<0.001).
There was no difference in the number of adverse events requiring dose reduction or prophylaxis discontinuation between the ganciclovir and the valacyclovir groups.
Clinical conclusions
The authors concluded that 3 months' treatment with valacyclovir for renal transplant recipients was as effective in preventing CMV disease and CMV DNAemia as oral ganciclovir. Valacyclovir was associated with a significantly reduced risk of acute rejection in comparison with both ganciclovir prophylaxis and deferred therapy.
Measure of benefits used in the economic analysis
The authors did not derive a measure of health benefit. The analysis was therefore categorised as a cost-consequences study.
Direct costs
The direct costs included were those of the hospital. These comprised all costs directly related to CMV, such as the costs of hospitalisation and treatment of CMV disease, the costs of prophylaxis, and the costs of diagnostic procedures on CMV activation and CMV monitoring post renal transplantation. The authors did not include the costs associated with the treatment of acute rejection episodes or other infections. The costs and the quantities were not reported separately. The sources of the unit costs used to value resource use were not reported. As the costs were incurred during one year, discounting was not relevant and was not performed. The study reported the average costs. The price year was not reported.
Statistical analysis of costs
The mean costs were reported alongside their standard deviations.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($). The conversion to US dollars was made using the average exchange rate over the course of the study (i.e. US$1 = 35.48 Czech crowns).
Sensitivity analysis
No sensitivity analyses were performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total 12-month direct CMV-related costs per patient were $3,072 (+/-2,006) for patients treated with ganciclovir, $2,906 (+/-2,433) for those receiving valacyclovir and $4,906 (+/-5,686) for those receiving deferred therapy.
This resulted in 37% and 41% cost-reductions with ganciclovir and valacyclovir, respectively, in comparison with deferred therapy.
